- cafead Mar 24, 2023 at 10:42: AM
via After a number of high-profile special purpose acquisition company announcements toward the end of last year, these deals once again dropped off in 2023. But that doesn’t mean the low-key revival of this reverse merger model has died.
Case in point is NKGen Biotech, a natural killer (NK) cell therapy-focused company, which announced plans to go public via a merger with blank-check company Graf Acquisition Corp. IV. Santa Ana, California-based NKGen was set up in 2017 with a focus on neurodegenerative diseases and oncology and is now led by Paul Song, M.D., who took the top seat in January after moving from Fuse Biotherapeutics.
article source
Case in point is NKGen Biotech, a natural killer (NK) cell therapy-focused company, which announced plans to go public via a merger with blank-check company Graf Acquisition Corp. IV. Santa Ana, California-based NKGen was set up in 2017 with a focus on neurodegenerative diseases and oncology and is now led by Paul Song, M.D., who took the top seat in January after moving from Fuse Biotherapeutics.
article source